Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₹ 311.7
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very strong margins and returns
Data is available to registered users only
Data is available to registered users only
About
Gujarat Themis Biosyn Ltd. operates as a pharmaceutical company. The firm engages in the manufacture of drugs. Its products include Rifamycin and Lovastatin. The company was founded on December 11, 1981 and is headquartered in Mumbai, India.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI
Data is available to registered users only
Buy
Sell